Telos Corporation
NASDAQ:TLSInformation Technology Services
-$0.01 today
- Market cap
- $544.88M
- Beta
- 0.97
- P/E (TTM)
- -12.4
- EPS (TTM)
- -$0.35
Volume 0.84M
Average 0.87M
TLS Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Telos CorporationNASDAQ: TLS
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue grows, but more slowly than its trailing trend
Q1 FY2026 revenue of $47.74M rose 55.9% year over year, behind the +66.5% change in trailing-twelve-month revenue. Sequentially, it rose 2.1% from the prior quarter. Over 3 fiscal years it compounded at -8.7% a year.
Context
- Revenue increased in 1 of the last 3 fiscal years.
What to watch
Whether revenue reaches the consensus estimate from 5 analysts of $199.74M (+21.2%) for the fiscal year ending Dec 2026, a slowdown from the +52.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $47.74M+2.1% QoQ
- Last fiscal yearDec 2025
- $164.81M+52.2% YoY
- LTMMar 2026
- $181.93M+66.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +55.9% | +25.6% | -30.4 pp |
| 1 year | +52.2% | +21.2% | -31.0 pp |
| 3-year CAGR | -8.7% | +11.8% | +20.5 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 164.81M USD
- Year-over-year change
- +52.2%
- 4-year CAGR
- -9.2%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 164.81M | +52.2% |
| FY2024 | 2024-12-31 | 108.27M | -25.5% |
| FY2023 | 2023-12-31 | 145.38M | -33.0% |
| FY2022 | 2022-12-31 | 216.89M | -10.5% |
| FY2021 | 2021-12-31 | 242.43M | — |
Revenue vs competitors
How TLS compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of +66.5% is the highest of 10, against a peer median of +3.3%.
- Over three fiscal years its annual growth of -8.7% compares with a peer median of +3.9%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $7.41B USD | +20.0% | -0.4% | |
| LTM Mar 2026 | $1.74B USD | +3.3% | +4.4% | |
| LTM Mar 2026 | $788.36M USD | +4.9% | +9.6% | |
| LTM Mar 2026 | $626.95M USD | +17.0% | +4.2% | |
| LTM Mar 2026 | $302.14M USD | +18.8% | -8.4% | |
| LTM Mar 2026 | $296.56M USD | -5.7% | +1.3% | |
| LTM Mar 2026 | $245.76M USD | +1.7% | +3.6% | |
| LTM Mar 2026 | $202.11M USD | -12.6% | +100.2% | |
| LTM Mar 2026 | $181.93M USD | +66.5% | -8.7% | |
NBPNovaBridge Biosciences | LTM Sep 2025 | CN¥0 CNY | -100.0% | — |
| Peer median (excluding TLS) | — | +3.3% | +3.9% | |
Competitors are the stored peer set for TLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 242.43M | 216.89M | 145.38M | 108.27M | 164.81M |
| Cost of Revenue | 156.4M | 137.84M | 92.44M | 73.84M | 103.79M |
| Gross Profit | 86.03M | 79.04M | 52.94M | 34.43M | 61.02M |
| Gross Margin | 35.5% | 36.4% | 36.4% | 31.8% | 37.0% |
| Research & Development | 19.1M | 16.92M | 12.25M | 8.44M | 7.06M |
| Selling, General & Admin | 108.4M | 115.98M | 81.01M | 75.49M | 78.93M |
| Operating Expenses | 127.49M | 132.89M | 93.26M | 90.3M | 85.53M |
| Depreciation & Amortization | 5.62M | 5.89M | 9.43M | 11.87M | 11.45M |
| EBITDA | (36.76M) | (46.61M) | (24.17M) | (39.98M) | (25.21M) |
| EBITDA Margin | -15.2% | -21.5% | -16.6% | -36.9% | -15.3% |
| Operating Income | (41.46M) | (53.85M) | (40.32M) | (55.87M) | (24.47M) |
| Operating Margin | -17.1% | -24.8% | -27.7% | -51.6% | -14.8% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 777K | 874K | 786K | 644K | 553K |
| Other Income / Expenses | (1.7M) | 476K | 5.93M | 3.38M | (12.74M) |
| Income Before Tax | (43.16M) | (53.37M) | (34.39M) | (52.49M) | (37.21M) |
| Pre-Tax Margin | -17.8% | -24.6% | -23.7% | -48.5% | -22.6% |
| Income Tax Expense | (28K) | 54K | 36K | 26K | (663K) |
| Net Income | (43.13M) | (53.43M) | (34.42M) | (52.52M) | (36.55M) |
| Net Margin | -17.8% | -24.6% | -23.7% | -48.5% | -22.2% |
| EPS (Basic) | (0.65) | (0.79) | (0.50) | (0.73) | (0.50) |
| EPS (Diluted) | (0.65) | (0.79) | (0.50) | (0.73) | (0.50) |
| Weighted Avg Shares | 66.37M | 67.56M | 69.26M | 71.85M | 72.88M |
| Weighted Avg Shares (Diluted) | 66.37M | 67.56M | 69.26M | 71.85M | 72.88M |
Telos Corporation
NASDAQ:TLS
Intrinsic Alpha fair value
Locked
Current Price
$7.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.